Why Patients Prefer Benzodiazepines Over Psychotherapy and Non-Addictive Anxiolytics
Patients prefer benzodiazepines because they provide rapid symptom relief, are easier to take than engaging in psychotherapy, and create a sense of immediate control over anxiety—but this preference comes at a significant cost to long-term outcomes including increased risk of dependence, mood disorders, and substance use disorders.
The Core Reasons for Patient Preference
Immediate Symptom Relief and Ease of Use
Benzodiazepines have a quick onset of action 1, 2, which makes them inherently more appealing than psychotherapy (which requires time, effort, and active participation) or non-addictive medications like SSRIs/SNRIs (which take 4-6 weeks to achieve therapeutic effect). The rapid anxiolytic effect creates immediate reinforcement that drives continued preference.
Enhanced Perceived Control
Patients using benzodiazepines on an as-needed (p.r.n.) basis report feeling greater control over their symptoms 3. This administration pattern is very common practice and increases with chronicity of use 3. The ability to take medication "when needed" creates an illusion of mastery over anxiety that psychotherapy—which requires sustained effort—cannot match in the short term.
Physician Prescribing Patterns Reinforce Preference
Benzodiazepines continue to be widely prescribed in non-psychiatric settings despite clinical guideline recommendations favoring SSRIs/SNRIs 4. The B/S ratio (benzodiazepine to SSRI/SNRI prescriptions) remains consistently higher in internal medicine than psychiatry 4, meaning patients are more likely to be offered benzodiazepines as first-line treatment in primary care settings where most anxiety is managed.
The Critical Problem: Preference Does Not Equal Better Outcomes
Long-Term Harms Outweigh Short-Term Benefits
The most recent and highest quality evidence demonstrates that benzodiazepine use for anxiety disorders is associated with dramatically increased long-term risk of mood and substance use disorders 5:
- Depressive disorders: HR 2.64 (95% CI 2.59-2.68)
- Bipolar disorders: HR 4.39 (95% CI 4.15-4.64)
- Overall substance use disorders: HR 3.00 (95% CI 2.92-3.08)
- Alcohol use disorder: HR 3.38 (95% CI 3.20-3.57)
This 2024 large-scale retrospective cohort study of 76,137 matched patients over 5 years provides the strongest evidence that patient preference for benzodiazepines leads to worse morbidity outcomes 5.
The Dependence Trap
Around half of patients dispensed benzodiazepines had been treated continuously for at least 12 months, a practice either not recommended by clinical guidelines or of doubtful efficacy 6. The guideline evidence shows that:
- Long-term benzodiazepine treatment leads to risks of adverse neurological effects, dependence, and withdrawal symptoms 6
- P.r.n. administration (the preferred method) may be associated with increased patient preference for benzodiazepines over placebo, continued use, and greater impairment on cognitive factors associated with positive long-term anxiety management 3
- Ironically, p.r.n. benzodiazepine administration may be associated with reduced anxiolytic efficacy over time 3
What Patients Actually Want vs. What They're Getting
Most primary care patients prefer psychological treatments for anxiety 7, yet they receive primarily pharmacological treatment 7. Only 28% of primary care patients with anxiety disorders received potentially adequate pharmacotherapy or CBT at baseline, and when treatment was provided, adequate pharmacotherapy (60%) was much more common than adequate CBT (36%) 7.
The Clinical Reality
The preference for benzodiazepines represents a mismatch between immediate symptom suppression and long-term recovery. Patients choose what feels better now (rapid relief, ease of use, perceived control) over what produces better outcomes later (psychotherapy, SSRIs/SNRIs with sustained efficacy and no dependence risk).
Common Pitfalls to Avoid
- Confusing patient satisfaction with clinical effectiveness: Rapid symptom relief creates satisfaction but not recovery
- Enabling p.r.n. use patterns: This administration method increases preference and dependence while potentially reducing efficacy 3
- Failing to offer or adequately support psychotherapy: The treatment patients actually prefer when properly informed 7 but rarely receive
- Ignoring the 12-month mark: Half of benzodiazepine patients reach continuous 12-month use 6, at which point dependence and withdrawal become major concerns
If there is a decision to stop benzodiazepines after long-term use, patients should be offered careful tapering and support 6, as sudden cessation leads to physical and psychological withdrawal symptoms.